country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-P11903

Copy Link Print Information

dTBP-3

dTBP-3 is a fully D-configured polypeptide competitive inhibitor that targets TIGIT. dTBP-3 can competitively occupy the binding interface between TIGIT and its ligand PVR, block TIGIT-mediated immunosuppressive signals, and reverse the immune exhaustion of NK cells and CD8⁺ T cells. dTBP-3 possesses anti-proteolytic activity and tumor tissue penetration ability, and can also enhance the tumor penetration capacity and cellular internalization efficiency of nanocarriers. dTBP-3 can be used in studies related to liver cancer, triple-negative breast cancer and non-small cell lung cancer.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Formule: C₇₀H₉₃N₂₁O₁₆
Masse moléculaire:1484.62

Stockage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Synthèse personnalisée de peptides

dTBP-3 Chemical Structure

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- In Vitro
- In Vivo
Chemical Information
Pureté et documentation
Références
Calculators
Help & FAQs
Classifications
Bioz

Activité biologique

Description

In Vitro

OthersAnti-cancer

Others

dTBP-3 can be completely released from DTBP-3NP-siANRIL within 6 h, while it remains tightly bound in the absence of GSH; in addition, dTBP-3-conjugated nanoparticles are taken up by Hep3B cells in a concentration-dependent manner, which inhibits Hep3B cell proliferation and induces apoptosis^[1].
dTBP-3 conjugated with PLLD forms DTBP-PLLD, which can be liberated from PR-T@PLLD in a pH-dependent pattern and displays elevated release efficiency under acidic lysosomal and tumor microenvironment conditions^[2].
dTBP-3-derived tracer [¹⁸F]TTDP binds to purified human TIGIT protein with a K_D value of 40.14 nM, confirming its high-affinity targeting to human TIGIT^[3].

Anti-cancer

dTBP-3 modification on PR-T@PLLD nanocarriers boosts cellular internalization and strengthens the cytotoxicity of co-loaded PTX and RC, with an IC₅₀ value of 9.57 μg/mL at 48 h; it also facilitates efficient lysosomal escape in anti-PD-1 resistant 4T1 triple-negative breast cancer cells, and yields superior cellular uptake together with reduced lysosomal retention relative to unmodified nanocarriers^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Anti-cancerInnate ImmunityAdaptive ImmunityApoptosisCytokines & ChemokinesOthers

Anti-cancer

Innate Immunity

Adaptive Immunity

Apoptosis

dTBP-3 inhibits hepatocellular carcinoma by blocking the TIGIT/PVR pathway to enhance tumor immunity, increase the proportions of NK cells and T cells, slow tumor growth, and prolong the survival of tumor-bearing mice^[1].

Anti-cancer

Adaptive Immunity

Innate Immunity

Cytokines & Chemokines

Apoptosis

dTBP-3 (40 mg/kg, administered via tail vein base injection once every 3 days for a total of 5 doses) can enhance the in vivo anti-tumor effect against anti-PD-1-resistant triple-negative breast cancer via the PR-T@PLLD nanoplatform, strengthen the activity of CD8⁺ cytotoxic T cells, remodel the tumor immune microenvironment, and promote the secretion of pro-inflammatory cytokines; it can also induce the formation of immune memory in the body and effectively inhibit lung metastasis of triple-negative breast cancer^[2].

Others

dTBP-3 can be used to synthesize the intravenous tracer [¹⁸F]TTDP. This probe specifically targets TIGIT-positive tumor-infiltrating lymphocytes in mice and humans, shows significantly higher tumor uptake than all control groups, can quantitatively reflect the intratumoral TIGIT expression level, predict the intervention effect of combined immunotherapy, and shares the same urinary metabolic clearance pathway in rhesus monkeys as in mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Related Protocols :

Chemical Information

Masse moléculaire 1484.62
Formule C₇₀H₉₃N₂₁O₁₆
Sequence

Gly-Gly-D-{Tyr-Thr-Phe-His-Trp-His-Arg-Leu-Asn-Pro}
Sequence Shortening

GGytfhwhrlnp
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

Please store the product under the recommended conditions in the Certificate of Analysis.

Pureté et documentation

Instruction de manipulation (2659 KB)

Références

[1]. Wang T, et al. TIGIT/PVR and LncRNA ANRIL dual-targetable PAMAM polymeric nanoparticles efficiently inhibited the hepatoma carcinoma by combination of immunotherapy and gene therapy. Journal of drug targeting. 2021 Aug;29(7):783-791.

[2]. Wang J, et al. Tumor targeting dendritic nanocarrier with immunogenic cell death inducing and TIGIT blockade for synergistic chemo-immunotherapy against TNBC. Journal of nanobiotechnology. 2025 Dec 07;23(1):759.

[3]. Wang J, et al. Development and characterisation of [F]TTDP, a novel T cell immunoglobulin and ITIM domain tracer, in humanised mice and non-human primates. European journal of nuclear medicine and molecular imaging. 2025 Jan;52(2):416-426.

Calculators

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Obtenir un devis En stock

Other size

Obtenir un devis

Amount: USD 0.00

Activité biologique
- Description
- In Vitro
- In Vivo
Chemical Information
Pureté et documentation
Références

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

dTBP-3

Activité biologique

Description

In Vitro

In Vivo

Chemical Information

Pureté et documentation

Références

Calculators

Help & FAQs

dTBP-3 Related Classifications

HY-P11903 Related Classifications

Bioz

Keywords

Your Recently Viewed Products